SCYNEXIS, Inc. (SCYX) Stock Price

SCYXStock

$5.19−19.45%52W

Market Cap$51.64M

P/E—

PEG Ratio—

Div yield—

Beta1.06

SCYX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-30.45%

Price vs S&P 500 (4W)41.85%

VGM Score74.36

Book Value / Share (Quarterly)$5.33

P/TBV (Annual)1.14x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)59.36%

Cash Flow / Share (Quarterly)$-0.76

Price vs S&P 500 (YTD)-8.01%

Gross Margin (TTM)100.00%

Net Profit Margin (TTM)-41.79%

EPS (TTM)$-2.92

10-Day Avg Trading Volume0.09M

EPS Excl Extra (TTM)$-2.92

Revenue Growth (5Y)99.01%

EPS (Annual)$-1.38

ROI (Annual)-17.44%

Gross Margin (Annual)100.00%

Net Profit Margin (5Y Avg)-409.20%

Cash / Share (Quarterly)$7.64

Revenue Growth QoQ (YoY)1808.50%

ROA (Last FY)-14.58%

Revenue Growth TTM (YoY)673.54%

EBITD / Share (TTM)$-1.42

ROE (5Y Avg)-401.32%

Operating Margin (TTM)-77.93%

Cash Flow / Share (Annual)$-0.97

P/B Ratio1.23x

P/B Ratio (Quarterly)0.99x

Net Income / Employee (Annual)$-478,300

EV / Revenue (TTM)0.69x

Net Interest Coverage (TTM)31.96x

ROA (TTM)-39.48%

EV / EBITDA (TTM)0.19x

EPS Incl Extra (Annual)$-1.38

Current Ratio (Annual)7.04x

Quick Ratio (Quarterly)3.92x

3-Month Avg Trading Volume0.11M

52-Week Price Return-19.45%

Revenue / Employee (TTM)$1,130,200

Tangible BV / Share (Quarterly)$1.96

P/S Ratio (Annual)2.47x

Asset Turnover (Annual)0.35x

52-Week High$10.48

Operating Margin (5Y Avg)-636.97%

EPS Excl Extra (Annual)$-1.38

Tangible BV CAGR (5Y)-33.31%

26-Week Price Return-19.20%

Quick Ratio (Annual)7.00x

13-Week Price Return-7.39%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)3.94x

Enterprise Value$14.27M

Revenue / Share Growth (5Y)29.25%

Asset Turnover (TTM)0.35x

Book Value / Share Growth (5Y)51.09%

Revenue / Employee (Annual)$1,144,500

Inventory Turnover (Annual)0.92x

Pretax Margin (Annual)-41.79%

Cash / Share (Annual)$7.36

3-Month Return Std Dev90.50%

Gross Margin (5Y Avg)75.47%

Net Income / Employee (TTM)$-1,362,100

ROE (Last FY)-17.44%

Net Interest Coverage (Annual)8.40x

EPS Basic Excl Extra (Annual)$-1.38

P/FCF (TTM)2.77x

Receivables Turnover (TTM)133.52x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-2.92

Receivables Turnover (Annual)133.47x

ROI (TTM)-57.16%

P/S Ratio (TTM)2.47x

Pretax Margin (5Y Avg)-431.52%

Revenue / Share (Annual)$3.30

Tangible BV / Share (Annual)$15.69

Price vs S&P 500 (52W)-37.76%

Year-to-Date Return3.95%

5-Day Price Return2.33%

EPS Normalized (Annual)$-1.38

ROA (5Y Avg)-16.97%

Net Profit Margin (Annual)-41.79%

Month-to-Date Return8.68%

EBITD / Share (Annual)$-2.58

Operating Margin (Annual)-78.03%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-27.82%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-2.92

P/TBV (Quarterly)1.14x

P/B Ratio (Annual)0.54x

Inventory Turnover (TTM)34.63x

Pretax Margin (TTM)-41.79%

Book Value / Share (Annual)$9.07

Price vs S&P 500 (13W)-10.19%

Beta1.06x

P/FCF (Annual)0.85x

Revenue / Share (TTM)$3.19

ROE (TTM)-57.16%

52-Week Low$3.53

vGradeA

gGradeA

mGradeC

vgmGradeB

SCYX Earnings Surprise History

Q2 25-1.12est. -1.52

Q3 25-1.36est. -1.60

Q4 252.00est. 1.01

Q1 26-3.36est. -0.99

Q2 260.63est. -0.51

SCYX Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.22

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
SCYXSCYNEXIS, Inc.	A	A	C	$5.19
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About SCYNEXIS, Inc.

SCYNEXIS develops novel antifungal therapies to treat serious fungal infections with significant unmet medical needs. The company's lead candidate, ibrexafungerp, is an oral and intravenous glucan synthase inhibitor demonstrating broad-spectrum activity against drug-resistant Candida and Aspergillus species. The medication's differentiated mechanism of action offers potential advantages over existing antifungal treatments for invasive fungal infections.